SFX by Ex Libris Inc.

Title:	Cross talk of tyrosine kinases with the DNA damage signaling pathways
Source:	Nucleic Acids Research [0305-1048] Mahajan, Kiran yr:2015

Basic

Full text

Full text available via PubMed Central

Year:

Volume:

Issue:

Start Page:

Document delivery

Request document via Library/Bibliothek

Users interested in this article also expressed an interest in the following:
description	1.	Bonifati, V. "Genetics of Parkinson's disease - state of the art, 2013." Parkinsonism & related disorders 20.SUPPL.1: 23-8.
description	2.	Schneider, Susanne A. "Precision medicine in Parkinson's disease: emerging treatments for genetic Parkinson's disease." Journal of neurology. 267.3: 860-869.
description	3.	Shulman, Joshua M. "Parkinson's Disease: Genetics and Pathogenesis." Annual review of pathology 6.1 (2010): 193-222.
description	4.	Brice, A. "Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects." American journal of human genetics 68.3 (2001): 617-26.
description	5.	Samii, A. "Parkinson's disease." The lancet 365.9459: 1783-1793.
description	6.	Singleton, A. "Genetics of Parkinson's disease and parkinsonism." Annals of neurology 60.4 (2006): 389-98.
description	7.	Nelson, S. "Parkinson's disease." Nursing standard 22.19 (2008): 59-60.
description	8.	Grayson, M. "Parkinson's disease." Nature 466.7310 (2010): 1-.
description	9.	Del Tredici, K. "Parkinson's Disease." Annals of the New York Academy of Sciences 1170.1 (2009): 615-622.
description	10.	Nichols, William C C. "Genetic screening for a single common LRRK2 mutation in familial Parkinson's disease." Lancet, The 365.9457 (2005): 410-2.
description	11.	Thomas, B. "Parkinson's disease." Human Molecular Genetics 16.R2 (2007): 183-94.
description	12.	Corti, O. "What Genetics Tells us About the Causes and Mechanisms of Parkinson's Disease." Physiological reviews 91.4 (2011): 1161-1218.
description	13.	O'Hara, Darren M. "Emerging disease-modifying strategies targeting α-synuclein for the treatment of Parkinson's disease." British Journal of Pharmacology 175.15 (2018): 3080-3089.
description	14.	Seeman, P. "Parkinson's Disease Treatment may cause Impulse-Control Disorder via Dopamine D3 Receptors." Synapse 69.4 (2015): 183-9.
description	15.	Tolosa, E. "Challenges in the diagnosis of Parkinson's disease." The Lancet neurology. 20.5: 385-397.
description	16.	Mollenhauer, B. "Baseline predictors for progression 4 years after Parkinson's disease diagnosis in the De Novo Parkinson Cohort (DeNoPa)." Movement disorders 34.1: 67-77.
description	17.	Goetz, Angelo G. "Medical and surgical management of motor complications in Parkinson's disease." Movement disorders 17.6 (2002): 900-908.
description	18.	Yang, David S X. "Molecular basis of Parkinson's disease." Neuroreport 20.2 (2009): 150-6.
description	19.	Jenner, P. "Etiology and pathogenesis of Parkinson's disease." Movement disorders 26.6 (2011): 1049-1055.
description	20.	Braak, H. "Staging of the intracerebral inclusion body pathology associated with idiopathic Parkinson's disease (preclinical and clinical stages)." Journal of neurology 249 Suppl 3.3 (2002): 1-5.